Description
Detects Ig G and Complement bound to Erythrocytes
COOMBS TEST DIRECT
Detects Ig G and Complement bound to Erythrocytes
TAT:
Specimen Type:
Hematology Single Test
Other Tests
-
60%
Absolute Eosinophil Count
Absolute eosinophil count is increased in allergic or atopic disease, infectious disorders (including parasites), medications, immunologic reactions, skin disorders, pulmonary syndromes, rheumatologic diseases, myeloproliferative neoplasms and secondary to other malignancies.
Absolute Eosinophil Count
Absolute eosinophil count is increased in allergic or atopic disease, infectious disorders (including parasites), medications, immunologic reactions, skin disorders, pulmonary syndromes, rheumatologic diseases, myeloproliferative neoplasms and secondary to other malignancies.
-
83%
Activated Partial Thromboplastin Time (APTT)
APTT measures intrinsic and common pathways of the coagulation cascade. Prolonged APTT may be caused by heparin and other anticoagulants, factor deficiencies or inhibitors such as lupus anticoagulants
Activated Partial Thromboplastin Time (APTT)
APTT measures intrinsic and common pathways of the coagulation cascade. Prolonged APTT may be caused by heparin and other anticoagulants, factor deficiencies or inhibitors such as lupus anticoagulants
-
209%
Bethesda Assay (Quantitative Factor VIII Inhibitor)
Factor VIII inhibitors are IgG antibodies which can occur in alloimmunised patients with Congenital Factor VIII deficiency or as autoantibodies.
Bethesda Assay (Quantitative Factor VIII Inhibitor)
Factor VIII inhibitors are IgG antibodies which can occur in alloimmunised patients with Congenital Factor VIII deficiency or as autoantibodies.
-
60%
Absolute Neutrophil Count
Absolute neutrophil count is increased in infections, a variety of inflammatory disorders, cytokine therapy and some myeloid neoplasms
Absolute Neutrophil Count
Absolute neutrophil count is increased in infections, a variety of inflammatory disorders, cytokine therapy and some myeloid neoplasms
Reviews
There are no reviews yet.